Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia

References

• International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels (Belgium): International Diabetes Federation; 2013.
   Google Scholar
• Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40.
   PubMed Web of Science ®Google Scholar
• Khavandi K, Amer H, Ibrahim B, et al. Strategies for preventing type 2 diabetes: an update for clinicians. Ther Adv Chronic Dis. 2013;4:242–261.
   PubMedGoogle Scholar
• Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14:933–946.
   PubMedGoogle Scholar
• Perreault L, Temprosa M, Mather KJ, et al. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care. 2014;37:2622–2631.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract. 2013;19:1–48.
   PubMed Web of Science ®Google Scholar
• Portero McLellan KC, Wyne K, Villagomez ET, et al. Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag. 2014;10:173–188.
   PubMed Web of Science ®Google Scholar
• Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88:1322–1335.
   PubMed Web of Science ®Google Scholar
• Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25:1129–1134.
   PubMed Web of Science ®Google Scholar
• Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116:151–157.
   PubMed Web of Science ®Google Scholar
• Levitzky YS, Pencina MJ, D’Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol. 2008;51:264–270.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–1046.
   PubMed Web of Science ®Google Scholar
• Tuso P. Prediabetes and lifestyle modification: time to prevent a preventable disease. Perm J. 2014;18:88–93.
   PubMedGoogle Scholar
• Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• Hill JO. Can a small-changes approach help address the obesity epidemic? A report of the Joint Task Force of the American Society for Nutrition, Institute of Food Technologists, and International Food Information Council. Am J Clin Nutr. 2009;89:477–484.
   PubMed Web of Science ®Google Scholar
• BELVIQ (lorcaserin hydrochloride) US Prescribing Information. Woodcliff Lake (NJ): Eisai Inc; 2014.
   Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–256.
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–3077.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20:1426–1436.
   PubMed Web of Science ®Google Scholar
• Aronne L, Shanahan W, Fain R, et al. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med. 2014;126:7–18.
   PubMed Web of Science ®Google Scholar
• Nesto R, Fain R, Shanahan W, et al. Lorcaserin can improve weight loss in patients with prediabetes and reduce progression to type 2 diabetes in obese and overweight patients. Presented at the American Diabetes Association 74th Scientific Sessions; 2014 June 13–17; San Francisco, California. #99-OR. Diabetes. 2014;63:A27.
   Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–S69.
   Google Scholar
• Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–980.
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists. Screening and monitoring of prediabetes [Internet]. [cited 2016 Apr 7]. Available from: http://outpatient.aace.com/prediabetes/screening-and-monitoring-prediabetes.
   Google Scholar
• Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:342–362.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37:912–921.
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–161.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.
   PubMed Web of Science ®Google Scholar
• Perreault L, Pan Q, Mather KJ, et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379:2243–2251.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2012. Diabetes Care. 2012;35:S11–S63.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. WHO/NMH/CHP/CPM/11.1. Geneva (Switzerland): WHO; 2011. p. 1–25.
   Google Scholar
• Alqahtani N, Khan WA, Alhumaidi MH, et al. Use of glycated hemoglobin in the diagnosis of diabetes mellitus and pre-diabetes and role of fasting plasma glucose, oral glucose tolerance test. Int J Prev Med. 2013;4:1025–1029.
   PubMedGoogle Scholar
• Guo F, Moellering DR, Garvey WT. Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. Metab Syndr Relat Disord. 2014;12:258–268.
   PubMed Web of Science ®Google Scholar
• Thomas DM, Martin CK, Redman LM. Lorcaserin improves dietary adherence: new insights from an energy balance analysis. Presented at Obesity Week; 2015 Nov 2–7; Los Angeles, CA.
   Google Scholar